{
  "pmcid": "9748994",
  "abstract": "1. A 250-word version\n\nTitle: Randomised Controlled Trial of Tranexamic Acid in Postpartum Haemorrhage\n\nBackground: The optimal dose of tranexamic acid (TXA) to inhibit hyperfibrinolysis in postpartum haemorrhage (PPH) is unclear. This study aimed to determine the doseâ€“effect relationship for two regimens of intravenous TXA versus placebo.\n\nMethods: In this double-blind, placebo-controlled, randomised trial, women experiencing PPH during Caesarean delivery were randomised to receive placebo (n=57), TXA 0.5 g (n=51), or TXA 1 g (n=53) across eight centres in France from March 2016 to December 2019. The primary outcome was the difference in the increase over baseline in plasma D-dimer level 120 min after infusion. Randomisation was computer-generated, and allocation was concealed. Blinding included patients, clinicians, and outcome assessors.\n\nResults: In the placebo group, hyperfibrinolysis was evidenced by a mean increase over baseline of 93% for D-dimer level at 120 min. A dose of TXA 1 g was associated with smaller increases over baseline (D-dimers: 38%, p=0.003 vs placebo). The 0.5 g dose was less potent, with non-significant reductions (D-dimers: 58%, p=0.06 vs placebo). Adverse events were more frequent in the 1 g group but not severe.\n\nInterpretation: Fibrinolytic activation was significantly inhibited by a dose of intravenous TXA 1 g but not 0.5 g. These findings suggest that a 1 g dose is necessary for effective inhibition of hyperfibrinolysis in PPH.\n\nTrial registration: NCT 02797119.\n\nFunding: The study was funded by independent agencies with no influence on the study design or reporting.",
  "word_count": 243
}